Technical Analysis for CLLS - Cellectis S.A.

Grade Last Price % Change Price Change
grade D 19.34 0.00% 0.00
CLLS closed down 2.08 percent on Tuesday, March 19, 2019, on 1.39 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical CLLS trend table...

Date Alert Name Type % Chg
Mar 19 Stochastic Reached Overbought Strength 0.00%
Mar 19 Inside Day Range Contraction 0.00%
Mar 19 Overbought Stochastic Strength 0.00%
Mar 18 Up 3 Days in a Row Strength -2.08%
Mar 18 Up 4 Days in a Row Strength -2.08%
Mar 18 Up 5 Days in a Row Strength -2.08%
Mar 15 Up 3 Days in a Row Strength 0.16%
Mar 15 Up 4 Days in a Row Strength 0.16%
Mar 15 Up 5 Days in a Row Strength 0.16%
Mar 14 Up 3 Days in a Row Strength 1.68%

Older signals for CLLS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Cellectis, a biopharmaceutical company, develops cancer products based on engineered T cells armed with a chimeric antigen receptor for the treatment of liquid and solid tumors. Its lead product candidate, UCART19, is an allogeneic engineered T cell product for the treatment of CD19 expressing hematologic malignancies that developed in chronic lymphocytic leukemia and acute lymphoblastic leukemia indications. The company's products also include hematopoietic tumors, such as UCART123 and UCART33 for acute myeloid leukemia indications, and UCART-BCMA and UCART38 for multiple myeloma indications, as well as solid tumors comprising UCART5T4 for various solid tumor indications and UCART-EgfrVIII for glioblastoma indications. In addition, it is focused on life sciences to build products based on genome engineering technologies in various fields and markets. Cellectis was founded in 1999 and is based in Paris, France.
Medicine Biopharmaceutical Cancer Solid Tumors Acute Myeloid Leukemia Multiple Myeloma Glioblastoma Leukemia Chronic Lymphocytic Leukemia Hematologic Malignancies Solid Tumor Oncogenes Adoptive Cell Transfer Tumors Of The Hematopoietic And Lymphoid Tissues Acute Lymphoblastic Leukemia Cellectis
Is CLLS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 38.85
52 Week Low 15.34
Average Volume 132,693
200-Day Moving Average 24.1748
50-Day Moving Average 17.688
20-Day Moving Average 18.4465
10-Day Moving Average 18.805
Average True Range 0.783
ADX 18.87
+DI 28.1159
-DI 15.052
Chandelier Exit (Long, 3 ATRs ) 17.571
Chandelier Exit (Short, 3 ATRs ) 18.949
Upper Bollinger Band 20.2732
Lower Bollinger Band 16.6198
Percent B (%b) 0.74
BandWidth 19.805383
MACD Line 0.4774
MACD Signal Line 0.3887
MACD Histogram 0.0887
Fundamentals Value
Market Cap 692.17 Million
Num Shares 35.8 Million
EPS -2.30
Price-to-Earnings (P/E) Ratio -8.41
Price-to-Sales 23.25
Price-to-Book 4.09
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.30
Resistance 3 (R3) 20.33 20.03 20.14
Resistance 2 (R2) 20.03 19.79 20.02 20.09
Resistance 1 (R1) 19.69 19.64 19.54 19.66 20.03
Pivot Point 19.39 19.39 19.32 19.38 19.39
Support 1 (S1) 19.05 19.15 18.90 19.02 18.65
Support 2 (S2) 18.75 19.00 18.74 18.59
Support 3 (S3) 18.41 18.75 18.54
Support 4 (S4) 18.38